Evolving treatment landscape for mCRPC
1.Tannock IA et al. N Engl J Med 2004;351:1502-12; 2. Ryan CJ et al.
Lancet Oncol 2015;16:152–60; 3. Beer TM et al. Eur Urol 2016: doi: 10.1016/j.eururo.2016.07.032 (epub ahead of print)
Abiraterone
(post-chemo)
2004
2010
2011
2012
2013
Docetaxel
Cabazitaxel
Abiraterone
(pre-chemo)
Mitoxantrone
2016
OS 18.9 mo
1
OS 35.3
mo
3
Zoledronic
acid
Enzalutamide
(pre-chemo)
Enzalutamide
(post-chemo)
Sipuleucel-T
OS 34.7 mo
2
Denosumab
Radium 223
SAEU.CAB.16.07.0040j
